Chinese Firms Up Their Game In Novel Flu Antiviral Development

24 Apr 2024

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

flu tablet — domestic commercial rights to three novel flu antivirals changed hands in China in 2023 • Source: Shutterstock

Chinese Firms Up Their Game In Novel Flu Antiviral Development

More from China

More from Focus On Asia